Cherwell Opens Expanded Redipor Prepared Media Manufacturing Facility
Cherwell Laboratories, manufacturer of Redipor prepared microbiological media, has completed an expansion programme at its Bicester-based facility. Initiated in response to a significant increase in demand, Cherwell has doubled the size of its cleanroom manufacturing suite and recruited additional staff to support the higher production capacity. Cherwell is renowned for offering a flexible supply of quality prepared media products, and the expanded facility ensures increasing demand in the UK and mainland Europe can be accommodated.
Cherwell’s continuing growth is partly fuelled by the development of export sales — up 55% in the past 2 years — and the appointment of further European distributors for the Redipor range. Already supported in Italy, Ireland, Poland and Slovenia, Cherwell has recently signed distributor agreements with AcefeSA in Spain and Dorte Egelund in Denmark. The company has carefully selected partners with the capability to deliver the same quality of service enjoyed by its UK customers.
The company has increased its UK market share through a dedication to customer service and the ability to deliver bespoke prepared media solutions. Many customers are switching to the convenience of Redipor pre-prepared media rather than making their own onsite. Increased pressure by regulators for more environmental monitoring has also led to overall growth in the prepared media market. Notably, demand for Redipor Barrier pack products, for use in isolators where vaporised hydrogen peroxide (VHP) is present, has grown, reflecting the increased use of VHP technology for sterilisation procedures.
Andy Whittard, Managing Director, Cherwell Laboratories commented: “This investment in facilities and capabilities is a clear indication of our commitment to developing our position as a leading supplier of prepared media. Recent market research shows our customers value not just the quality of our products, but increasingly our service and support. Most importantly, we are consistently delivering what our customers want.”
He added: “By developing our export markets through carefully selected partners, we aim to continue growing our UK-based production in a controlled manner, keeping excellent service and the customer at the core of what we do.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...